Semaglutide
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 572
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Treatment group A: HRS9531 injection | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group B: Semaglutide Injection | Obesity or overweight | n/r | n/r | n/r | n/r |